Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 5/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | PNP | P00491 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7276846 | 0.80 | PDE4A (0.45) | ARPTGS1PTGS2GAAPDE4A | |
| Hydrochloric Acid SCHEMBL7274487 | 0.79 | PDE4A (0.44) | ARPTGS1PTGS2GAAPDE4A | |
| SCHEMBL5370463 | 0.79 | CYP3A4 (0.63) | ARPTGS1PTGS2HTR2CCNR2 | |
| SCHEMBL28149817 | 0.78 | HTR2C (0.51) | ARHTR2CKDM1AGAAHSD17B10 | |
| SCHEMBL3215294 | 0.76 | AKR1B1 (0.43) | AR | |
| SCHEMBL16429432 | 0.75 | CYP1A2 (0.50) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6236041 | 0.74 | AKR1B1 (0.69) | ARPTGS1PTGS2 | |
| SCHEMBL16861315 | 0.74 | AR (0.46) | ARHTR2CKDM1AGAAHSD17B10 | |
| SCHEMBL27768176 | 0.74 | AR (0.46) | ARHTR2CKDM1AGAAHSD17B10 | |
| SCHEMBL27916991 | 0.73 | MTNR1A (0.48) | ARPTGS1PTGS2KDM1AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0809490-A4 | USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION | SMITHKLINE BEECHAM CORP (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0871436-A4 | USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS | SMITHKLINE BEECHAM CORP (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0835104-A4 | USE OF STAT 5 SH2 DOMAIN SPECIFIC COMPOUNDS TO ENHANCE ERYTHROPOIESIS | SMITHKLINE BEECHAM CORP (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0871436-A1 | USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-21 | — | — | EP | disclosed |
| EP-0835104-A1 | USE OF STAT 5 SH2 DOMAIN SPECIFIC COMPOUNDS TO ENHANCE ERYTHROPOIESIS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-15 | — | — | EP | disclosed |
| EP-0809490-A1 | USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1997002024-A1 | USE OF STAT 5 SH2 DOMAIN SPECIFIC COMPOUNDS TO ENHANCE ERYTHROPOIESIS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-23 | — | — | WO | disclosed |
| WO-1997002023-A1 | USE OF Stat 6 SH2 DOMAIN SPECIFIC COMPOUNDS TO TREAT ALLERGIC REACTIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-23 | — | — | WO | disclosed |
| EP-0728482-A2 | Use of hcp specific compounds to enhance erythropoiesis | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-28 | — | — | EP | disclosed |
| EP-0727211-A1 | Use of src SH2 specific compounds to treat a bone resorption disease | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-21 | — | — | EP | disclosed |
| WO-1996024343-A1 | USE OF LCK SH2 SPECIFIC COMPOUNDS TO TREAT AUTOIMMUNE DISEASES AND ALLOGRAFT REJECTION | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-15 | — | — | WO | disclosed |
| US-5061798-A | Intermediates in the formation of synthetic hormones, mimic effects of thyroid hormones; little or no effect on the heart | SMITH KLINE & FRENCH LABORATORIES, LTD. (GB) | 1991-10-29 | — | — | US | disclosed |
| EP-0188351-B1 | CHEMICAL COMPOUNDS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1991-03-13 | — | — | EP | disclosed |
| US-4910305-A | Containing a protected 4-hydroxyphenyl | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-03-20 | — | — | US | disclosed |
| US-4826876-A | WITHOUT EFFECT ON HEART | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-05-02 | — | — | US | disclosed |
| US-4766121-A | NOT AFFECTING THE HEART | SMITH KLINE & FRENCH LABORATORIES LTD. (GB) | 1988-08-23 | — | — | US | disclosed |
| EP-0188351-A2 | Chemical compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-07-23 | — | — | EP | disclosed |